Latest Medical Technology News

dorsaVi reports transformative performance improvements from integrating RRAM technology into its biomedical sensor platforms, promising faster, more durable, and energy-efficient wearable devices.

4DMedical has renewed its three-year contract with the University of Michigan Medical Center, reinforcing its foothold in US respiratory imaging. Alongside, a pivotal clinical study validates its technology’s ability to detect early lung disease, while a substantial Australian grant boosts its AI research.

EBR Systems has received preliminary approval from the U.S. Centers for Medicare & Medicaid Services for outpatient reimbursement of its WiSE® CRT System, marking a major step toward broader hospital adoption.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

Echo IQ has secured a pivotal reseller agreement with US-based SARC MedIQ, unlocking access to over 300 healthcare facilities and accelerating adoption of its AI-driven EchoSolv AS technology across the American cardiology landscape.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.

Artrya Limited has secured a five-year, US$0.6 million contract with Tanner Health, marking its inaugural commercial revenue in the U.S. market for its AI-powered Salix Coronary Anatomy platform.

Resonance Health is expanding its clinical trial operations with a third TrialsWest site in Mandurah, WA, set to open in August 2025, enhancing participant recruitment and supporting ongoing pharmaceutical trials.

Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.

Ryder Capital Limited has reported an impressive 27.5% pre-tax net tangible asset return for FY25, significantly outperforming key benchmarks and raising its fully franked final dividend to 5.5 cents per share.

dorsaVi has begun critical testing of its innovative RRAM-powered sensor systems in Singapore, targeting biomedical applications like EMG and ECG to enhance wearable device performance and energy efficiency.

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.